Recurrent Predictive Power of Circulating Tumor Cells for Non Small Cell Lung Cancer Patients

Study Overview
=================
Brief Summary
-----------------
From literature review, circulating tumor cell was demonstrated its possible role in disease relapse. It was rare nit could be identified in all lung cancer patients. In addition, circulating tumor cell usual aggregate to form circulating tumor micro-emboli and caused distant metastases. Therefore, circulating tumor cell could play a role in detect disease relapse and appropriate treatment could be given more earlier and further prolong patients' survival. However, the detail clinical significance of circulating tumor still remains unknown. The aim of this study was evaluate the clinical significance, including present timing, numbers, and correlation to disease relapse, of circulating tumor cell in lung cancer patients. The investigators want to clarify the clinical significance between circulating tumor cell and clinical presentation of lung cancer in order to establish new prediction model and improve lung cancer patients' survival.

Detailed Description
-----------------
Study subject: Inclusion criteria 1. Patients with clinical stage 1 to 3a non-small lung cancer 2. Patients with a resectable suspicious pulmonary lesion which is difficult for pre-operation tissue prove or refused for pre-operation biopsy 3. Received curative intended tumor resection Exclusion criteria Small cell lung cancer component which identified in pathology Patients who presented as stage IIIb or IV Not received curative intended surgery due to multi-comorbidities Patients who presented in tumor seeding or positive resection in pathology confirmation Patients who received neoadjuvant therapy Data collection: medical record review and blood sampling for circulating tumor cell purification Timing of blood sampling: a.Pre-operation, post-operation, post-operation day 1, post-operation day 3 b regular OPD surveillance (3 month-interval) for 3 years Blood sampling: 20 ml blood that withdrawn from a peripheral vein Circulating tumor cell purification: two-step procedure cell isolation: centrifugation, isolated karyocyte > 10 micrometer negative selection: wash out RBC, WBC depletion positive selection: purify circulating tumor cell (karyocyte which presented CD 45 negative, Epi-CAM positive, diameter greater 10 micrometer Result analysis: Combine the medical record to analyze the relationship between circulating tumor cells and disease relapse

Official Title
-----------------
Recurrent Predictive Power of Circulating Tumor Cells in Non Small Cell Lung Cancer Patients Who Receive Curative Resection

Conditions
-----------------
Lung Cancer Recurrent

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-small cell lung cancer patients with stage I to III Patients with resectable suspicious pulmonary malignant lesion no pre-operation diagnosis ( patients refused biopsy or difficult for biopsy) image survey showed clinical stage I to III Exclusion Criteria: Final pathology coexisted with small cell lung cancer component Patients who presented as stage IIIb or IV. Not received curative intended surgery due to multi-comorbidities. Patients who presented in tumor seeding or positive resection in the final pathology Patients who received neoadjuvant therapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Variation trend of circulating tumor cell counts | Relationship between variation trend of circulating tumor cells and disease relapse in patients with a suspicious pulmonary lesion after tumor resection | 1. Circulating tumor cell counts in pre-op, post-op, post-operation day 1 and post-operation day 3 ; 2.need complete 5-years surveillance (disease status confirmation) | 
| Validation of variation trend of circulating tumor cell counts | sequence patient recruitment for validation | 1. Circulating tumor cell counts in pre-op, post-op, post-operation day 1 and post-operation day 3 ; 2.model establish model (case 1 to 50) versus validation group ( case 51-120) 3. need complete 5-years surveillance (disease status confirmation) |